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ABSTRACT: Benzo[a]pyrene (BaP) is a human carcinogen that covalently binds to DNA 
after activation by cytochrome P450 (P450). Here, we investigated whether 
NADH:cytochrome b5 reductase (CBR) in the presence of cytochrome b5 can act as sole 
electron donor to human P450 1A1 during BaP oxidation and replace the canonical 
NADPH:cytochrome P450 reductase (POR) system. We also studied the efficiencies of 
coenzymes of these reductases, NADPH as a coenzyme of POR, and NADH as a coenzyme of 
CBR, to mediate BaP oxidation. Two systems containing human P450 1A1 were utilized: 
human recombinant P450 1A1 expressed with POR, CBR, epoxide hydrolase and cytochrome 
b5 in Supersomes™ and human recombinant P450 1A1 reconstituted with POR and/or with 
CBR and cytochrome b5 in liposomes. BaP-9,10-dihydrodiol, BaP-7,8-dihydrodiol, BaP-1,6-
dione, BaP-3,6-dione, BaP-9-ol, BaP-3-ol, a metabolite of unknown structure, and two BaP-
DNA adducts were generated by the P450 1A1-Supersomes™ system, both in the presence of 
NADPH and in the presence of NADH. The major BaP-DNA adduct detected by 32P-
postlabeling was characterized as 10-(deoxyguanosin-N2-yl)-7,8,9-trihydroxy-7,8,9,10-
tetrahydro-BaP (assigned adduct 1), while the minor adduct is probably a guanine adduct 
derived from 9-hydroxy-BaP-4,5-epoxide (assigned adduct 2). BaP-3-ol as the major 
metabolite, BaP-9-ol, BaP-1,6-dione, BaP-3,6-dione, an unknown metabolite, and adduct 2 
were observed in the system using P450 1A1 reconstituted with POR plus NADPH. When 
P450 1A1 was reconstituted with CBR, and cytochrome b5 plus NADH, BaP-3-ol was the 
predominant metabolite, too, and an adduct 2 was also generated. Our results demonstrate that 
the NADH/cytochrome b5/CBR system can act as the sole electron donor both for the first and 
second reduction of P450 1A1 during the oxidation of BaP in vitro. They suggest that NADH-
dependent CBR can replace NADPH-dependent POR in the P450 1A1-catalyzed metabolism 
of BaP. 
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INTRODUCTION 
Benzo[a]pyrene (BaP) (Figure 1) is a polycyclic aromatic hydrocarbon (PAH) that has been 
classified as human carcinogen (Group 1) by the International Agency for Research on 
Cancer.1 It is a pro-carcinogen requiring metabolic activation catalyzed by cytochrome P450 
(P450) enzymes prior to reaction with DNA.2 Among the P450s, P450 1A1 is the most 
important enzyme, in combination with microsomal epoxide hydrolase (mEH), involved in the 
metabolic activation of BaP to species forming DNA adducts.2,3 First, P450 1A1 oxidizes BaP 
to an epoxide (i.e. BaP-7,8-epoxide) that is then converted to a dihydrodiol by mEH (i.e. BaP-
7,8-dihydrodiol). Further bioactivation by P450 1A1 leads to the ultimate reactive species, 
BaP-7,8-dihydrodiol-9,10-epoxide (BPDE) that can react with DNA, forming adducts 
preferentially at guanine residues (Figure 1). The 10-(deoxyguanosin-N2-yl)-7,8,9-trihydroxy-
7,8,9,10-tetrahydrobenzo[a]pyrene (dG-N2-BPDE) adduct is the major product of the reaction 
of BPDE with DNA in vitro and in vivo.4-10 However, BaP is also oxidized to other 
metabolites such as other dihydrodiols, BaP-diones and further hydroxylated metabolites.2,6,11-
16
 Although most of these metabolites are detoxification products, BaP-9-ol is the precursor of 
9-hydroxy-BaP-4,5-epoxide that can form another adduct with deoxyguanosine in DNA 
(Figure 1).7,8,10,15,17-19  
The P450 enzymes, including P450 1A1, are components of a mixed-function oxidase 
(MFO) system located in the membrane of endoplasmic reticulum (microsomes). This 
enzymatic system also contains other enzymes, the multidomain flavoprotein 
NADPH:cytochrome P450 oxidoreductase (POR) and cytochrome b5 accompanied by its 
NADH:cytochrome b5 reductase (CBR). Mammalian microsomal P450s function by 
catalyzing the insertion of one atom of molecular oxygen into a variety of xenobiotics, 
including BaP, while reducing the other atom to water, a reaction that requires two 
electrons.20 The oxygen is activated in the active center of P450s by two electrons. It is 
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generally accepted that POR with NADPH serves as donor of electrons for both reductions of 
P450 in the MFO reaction cycle.20 However, the second electron may also be provided by 
CBR with cytochrome b5 and NADH, but cytochrome b5 seems to have also additional roles 
in the monooxygenase system.20-28 
Although POR is considered an essential constituent of the electron transport chain 
towards P450,20 its exact role in the P450-mediated reaction cycle is still not clearly 
established. Recently we used two mouse models, in which the expression of POR has been 
permanently (the Hepatic P450 Reductase Null (HRN) line) or conditionally (the Reductase 
Conditional Null (RCN) line) deleted in hepatocytes leading to a lack of almost all hepatic 
POR activity. Despite this lack of POR the levels of the P450-mediated dG-N2-BPDE adducts 
in the livers of mice of both lines exposed to BaP were higher than in BaP-treated wild-type 
mice.7,8,19 These findings suggested BaP activation in other liver cells other than hepatocytes 
(e.g. Kupffer or endothelial cells),29 or bioactivation of BaP by non-P450 enzymes (e.g. 
prostaglandin H synthase and lipoxygenases),30,31 or combinations of these mechanisms were 
operative. However, these phenomena might also indicate that another reductase such as 
microsomal CBR can contribute to the P450-mediated BaP oxidation in these animal models. 
The latter possibility is supported by  experiments with rat P450s indicating the involvement 
of cytochrome b5 in the NADH-dependent hydroxylation of BaP in a reconstituted P450-
containing system.32,33 Studies using cytochrome b5-knockout mouse lines, namely, HBN 
mice (Hepatic cytochrome b5 Null) with a conditional hepatic deletion of cytochrome b5, and 
HBRN mice (Hepatic cytochrome b5/P450 Reductase Null), in which POR and cytochrome b5 
are deleted specifically in the liver, also indicate the involvement of CBR in the P450-
mediated metabolism of some other P450 substrates.27,34,35  
We have recently demonstrated that the NADH/cytochrome b5/CBR system is indeed 
able to function as the sole electron donor for both reduction steps of rat P450 1A1 during 
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oxidation of BaP in vitro.15 Although this function of the NADH/cytochrome b5/CBR system 
is valid for rat P450 1A1, its role in the reaction cycle catalyzed by the human ortholog of 
P450 1A1 remained to be explored. To address this question, the present study was carried 
out, in which we utilized enzymatic systems containing recombinant human P450 1A1 over-
expressed in Supersomes™ or pure human recombinant P450 1A1 reconstituted with CBR 
and cytochrome b5 in liposomes. Results presented here provide evidence that the 
NADH/cytochrome b5/CBR system can function as the sole electron donor to human P450 
1A1 during BaP oxidation in vitro. 
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EXPERIMENTAL PROCEDURES 
Cautions: BaP is human carcinogen and should be handled with care. Exposure to 32P 
should be avoided, by working in a confined laboratory area, with protective clothing, 
plexiglass shielding, Geiger counters, and body dosimeters. Wastes must be discarded 
according to appropriate safety procedures. 
Chemicals and Material.  BaP (CAS no. 50-32-8; purity ≥96%), NADH (as disodium 
salt; purity ∼95%), NADPH (as tetrasodium salt; purity ∼98%), dilauroyl 
phosphatidylcholine, glutathione, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), dimethyl sulfoxide (DMSO), 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate hydrate (CHAPS) and calf thymus DNA were purchased from Sigma-
Aldrich (St. Louis, MO, USA) in ACS purity (purity meets the standards of American 
Chemical Society), unless stated otherwise. P450 1A1-Supersomes, microsomes isolated 
from insect cells transfected with a baculovirus construct containing cDNA of human P450 
1A1 and POR that are therefore over-expressed in these microsomes, were purchased from 
Gentest Corp. (Woburn, MI, USA). However, because they are microsomes (particles of 
broken endoplasmic reticulum), other enzymes (proteins) of the endoplasmic reticulum 
membrane [i.e. NADH:cytochrome b5 reductase (CBR), microsomal EH (mEH) and 
cytochrome b5] are also expressed at basal levels in these Supersomes™ (Gentest Corp., 
Woburn, MI, USA).  
Preparation of Human Recombinant P450 1A1 and Rat Recombinant POR. Human 
recombinant P450 1A1 (EC 1.14.14.1) and rat POR (EC 1.6.2.4) were prepared by 
heterologous expression in E. coli and purified to apparent homogeneity (i.e. as single bands 
on sodium dodecyl sulfate-polyacrylamide gel electrophoresis) as described recently.36 The 
specific content of human recombinant CYP1A1 was 11.5 nmol/mg protein. The specific 
activity of rat recombinant POR measured with cytochrome c as a substrate was 49.7 µmol 
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cytochrome c/min/mg protein. Both recombinant enzymes were utilized in the reconstitution 
experiments.37  
Isolation of Rat NADH:Cytochrome b5 Reductase and Rabbit Cytochrome b5. 
Cytochrome b5 reductase (CBR) (E.C. 1.6.2.2) was isolated from rat liver microsomes by a 
procedure described by Perkins and Duncan.38 The specific activity of rat CBR measured as 
NADH-ferricyanide reductase was 49.2 µmol ferricyanide/min/mg protein. Cytochrome b5 
was isolated from rabbit liver microsomes as described.39 Both proteins purified to apparent 
homogeneity38,39 were utilized in the reconstitution experiments.  
Determination of P450 and Protein Content. The concentration of P450 was estimated 
according to Omura and Sato,40 based on the absorption of the complex of reduced P450 with 
carbon monoxide. The P450 1A1 content was calculated using an extinction coefficient of 91 
mM−1 ·  cm−1 and estimated to be 11.5 nmol per mg protein. Protein concentrations were 
determined using a bicinchonic acid assay (BCA; Thermo Fisher Scientific, Waltham, MA, 
USA) with bovine serum albumin as a standard.41 
Reconstitution of Human P450 1A1 with POR or CBR in the Absence and Presence 
of Cytochrome b5 in Liposomes. Reconstitution of human P450 1A1 with POR, CBR and/or 
cytochrome b5 in liposomes was carried out as described previously19,37 with small 
modification. Briefly, dilauroyl phosphatidylcholine was dissolved in chloroform (20 mg/ml) 
and a lipid film was obtained by evaporation of chloroform by a stream of nitrogen. The lipid 
film was dispersed with 50 mM HEPES/KOH buffer, pH 7.4, containing 3 mM reduced 
glutathione, 0.1 µM CHAPS and sonicated twice at 20°C for 3 min. The appropriate amounts 
of human recombinant P450 1A1 and rat recombinant POR or human recombinant P450 1A1 
and purified rat CBR (200 pmol in a ratio of 1:1), without or with cytochrome b5 (in a ratio of 
P450 1A1 with reductase to cytochrome b5 of 1:5) were added to the prepared dispersion and 
incubated at 20°C for 10 min. As shown in previous studies,19,25,37,42,43 the enzymatic activity 
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of human P450 1A1 reconstituted with POR and cytochrome b5 from several animal models 
was the same as that of the enzyme reconstituted with the human orthologs of these enzymes. 
Incubations to Study the Metabolism of BaP by Human Recombinant P450 1A1 in 
Supersomes™ or by Human Recombinant P450 1A1 Reconstituted with POR or CBR in 
the Presence or Absence of Cytochrome b5 in Liposomes. Incubation mixtures used to 
study BaP metabolism by human recombinant P450 1A1 in the presence of other components 
of the MFO-systems in Supersomes™ contained 100 mM potassium phosphate buffer (pH 
7.4), 1 mM  NADPH or NADH, 50 µM  BaP (dissolved in 5 µl DMSO) and 100 nM human 
recombinant P450 1A1 in a final volume of 0.5 ml. The same amount of a solvent (DMSO) 
was used in control incubations without BaP. With this DMSO concentration (1 % as a final 
concentration) no inhibition of the NADPH-dependent P450-catalyzed oxidation of several 
substrates has been found previously.7,8,19,25,28,44 The reaction was initiated by adding the 
NADPH or NADH.  
In separate experiments 100 nM pure human recombinant P450 1A1 reconstituted 
individually with other components of the MFO-system was used instead of P450 1A1 in 
Supersomes™. Negative control reactions lacked either P450 1A1, reductases or BaP. After 
incubation (37°C, 20 min), 5 µl of 1 mM phenacetin in methanol was added as an internal 
standard. BaP metabolism by the P450 1A1 systems has been shown to be linear up to 30 min 
of incubation.15,16,19 BaP metabolites were extracted twice with ethyl acetate (2 × 1 ml), the 
solvent was evaporated to dryness, the residues were dissolved in 25 µl methanol and 
subsequently BaP metabolites were separated by HPLC as reported.19,45 BaP metabolite peaks 
were analyzed by HPLC by comparison with metabolite standards whose structures were 
determined previously by NMR and/or mass spectrometry.19  
Determination of BaP-DNA Adduct Formation by 32P-postlabeling. Incubation 
mixtures used to assess DNA adduct formation by BaP activated with all enzymatic systems 
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containing human P450 1A1 consisted of 50 mM potassium phosphate buffer (pH 7.4), 1 mM 
NADPH or NADH, 100 nM human recombinant P450 1A1 plus other enzymes as indicated in 
the figures (or as described above), 0.1 mM BaP (dissolved in 7.5 µl DMSO), and 0.5 mg of 
calf thymus DNA in a final volume of 0.75 ml as described previously.19 The reaction was 
initiated by adding 0.1 mM BaP and incubations were carried out at 37°C for 60 min. BaP-
DNA adduct formation has been shown to be linear up to 90 min.7,19 Control incubations were 
carried out without P450 1A1, or without reductases, or without cytochrome b5, or without 
NADPH (or NADH), or without DNA, or without BaP. After the incubation, DNA was 
isolated from the residual water phase by standard phenol/chloroform extraction. DNA adduct 
formation was analyzed using the nuclease P1 version of the 32P-postlabeling technique.7,19  
Resolution of the adducts by thin-layer chromatography (TLC) using polyethylenimine-
cellulose plates (Macherey and Nagel, Düren, Germany) was carried out as described.7,19,46 
DNA adduct levels (RAL, relative adduct labelling) were calculated as described.47 
Statistical Analyses.  Statistical analyses were carried out on the means ± standard 
deviations of three parallel experiments with Student’s t-test (UNISTAT Statistics Software 
v6, Unistat Ltd., Highgate, London N6 5UQ, UK) and p < 0.05 was considered significant. 
Statistical association between amounts of BaP metabolites formed by oxidation of BaP by 
the P450 reconstituted systems containing POR or CBR and levels of BaP-DNA adduct 2 
formed by the same systems were determined by the Spearman correlation coefficients using 
version 6.12 Statistical Analysis System software. Spearman correlation coefficients were 
based on a sample size of 6. All Ps are two-tailed and considered significant at the 0.05 level. 
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RESULTS  
Oxidation of BaP by Human P450 1A1 Expressed in Supersomes™ and Pure Human 
Recombinant P450 1A1 Reconstituted with POR or CBR. In order to evaluate the role of 
POR and CBR in the reduction of human P450 1A1 during BaP oxidation, two enzymatic 
systems containing this human P450 were utilized. The first system used Supersomes 
containing human recombinant P450 1A1 expressed with POR, CBR, mEH and/or 
cytochrome b5. In the second system, pure human recombinant P450 1A1 was reconstituted in 
liposomes with either pure POR or CBR. The latter enzymatic system was utilized with or 
without cytochrome b5 to examine the function of both reductases as electron donors to P450 
1A1 during BaP metabolism with NADPH (cofactor of POR) or NADH (cofactor of CBR). 
The BaP metabolites formed by human P450 1A1 in these enzyme systems were analyzed by 
HPLC (Figure 2A).  
Seven BaP metabolites were formed in Supersomes™ containing human P450 1A1, both 
in the presence of NADPH and NADH (Figure 2). They were structurally characterized 
previously16,19 as BaP-9,10-dihydrodiol (M1), BaP-7,8-dihydrodiol (M3), BaP-1,6-dione 
(M4), BaP-3,6-dione (M5), BaP-9-ol (M6) and BaP-3-ol (M7). The structures of these BaP 
metabolites are shown in Figure 2B. In addition, a metabolite of unknown structure (Mx) was 
detected. Essentially no BaP metabolites were found when both NADPH and NADH were 
omitted from the incubation mixtures containing the P450 1A1-Supersomes (Figure 2C). 
NADH was less effective than NADPH to act as electron donor to human P450 1A1 in 
Supersomes™ (Figure 2C). Addition of cytochrome b5 to the incubation mixtures led to an 
increase in P450 1A1-mediated BaP oxidation both in the presence of NADPH and in the 
presence of NADH (Figure 2C). 
In the second enzymatic system, where pure human recombinant P450 1A1 was 
reconstituted with POR with or without cytochrome b5 in liposomes, this P450 enzyme was 
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also able to oxidize BaP in the presence of NADPH (Figure 3). Only five BaP metabolites 
were formed, which were BaP-3-ol (M7) as the major metabolite, BaP-9-ol (M6), BaP-1,6-
dione (M4), BaP-3,6-dione (M5) and metabolite Mx (Figure S1). Because mEH was absent 
from the system, no dihydrodiols were formed. Addition of cytochrome b5 to this P450 1A1 
system increased formation of all BaP metabolites, in particular BaP-3-ol (Figure 3 and 
Figure S1). In contrast, NADH did not lead to significant BaP oxidation by P450 1A1 
reconstituted with POR (Figure 3 and Figure S1), which confirms that NADH functions as a 
coenzyme of POR at very slow rate that is negligible relative to NADPH, as we showed 
recently with cytochrome c as a substrate for POR.15 No BaP metabolites were found when 
both NADPH and NADH were omitted from the incubation mixtures containing the human 
recombinant P450 1A1 reconstituted with POR or CBR (Figure 3). 
In the enzymatic system where human P450 1A1 was reconstituted with CBR and 
cytochrome b5 in liposomes, BaP was predominantly oxidized to BaP-3-ol (M7) and to a 
lower extent to BaP-9-ol (M6), BaP-1,6-dione (M4), BaP-3,6-dione (M5) and a metabolite 
Mx (Figure S1). Cytochrome b5 as a substrate of CBR was necessary for BaP oxidation in the 
system of human P450 1A1 reconstituted with CBR with NADH as cofactor. Without this 
protein, essentially no BaP oxidation was detectable by P450 1A1 reconstituted with CBR 
(Figure 3 and Figure S1). Addition of POR to the reconstituted system of human P450 1A1 
with CBR and cytochrome b5 did not change BaP metabolite levels (Figure 3 and Figure S1).  
Formation of BaP-DNA adducts by human P450 1A1 expressed in Supersomes™ 
and by human P450 1A1 reconstituted with POR or CBR. In further experiments, the 
formation of DNA adducts by BaP incubated with human P450 1A1 expressed in 
Supersomes™ and human P450 1A1 reconstituted with POR or CBR was analyzed. First, we 
utilized human recombinant P450 1A1 expressed in Supersomes™ with other enzyme 
components of the microsomal monooxygenase system. Up to two DNA adducts (assigned 
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adducts 1 and 2; see insert in Figure 1) were detected by 32P-postlabeling in incubations where 
BaP was activated with human P450 1A1 in Supersomes™, in the presence of either NADPH 
or NADH. No such BaP adducts were found when both NADPH and NADH were omitted 
from the incubation mixtures containing the P450 1A1-Supersomes (Figure 4). Adduct 1 
was the BaP-DNA adduct predominantly formed in this system (Figure 4). Comparison with 
previous 32P-postlabeling analyses10,19 showed that adduct 1 is the dG-N2-BPDE adduct.10,19 
The other adduct, which was formed in this enzymatic system as only a minor product, if 
detectable at all (e.g. there was no formation of this adduct in Supersomes™ in the presence 
of NADPH), has similar chromatographic properties by TLC to a guanine adduct derived 
from reaction with 9-hydroxy-BaP-4,5-epoxide (see adduct spot 2 in insert of Figure 1 and 
Figure 5A). Addition of cytochrome b5 to P450 1A1 in Supersomes™, increased the levels of 
the dG-N2-BPDE adduct generated by human P450 1A1 in the presence of NADH (Figure 4), 
similar to the increase observed in BaP oxidation (Figure 2).  
Pure human recombinant P450 1A1 reconstituted with POR in the presence of NADPH 
formed only adduct 2 (Figures 5B and 6). Because of the absence of mEH, no adduct 1 (i.e. 
dG-N2-BPDE) was formed. Addition of cytochrome b5 to this P450 1A1 system decreased the 
levels of adduct 2, but this decrease was not statistically significant (Figure 6). NADH was 
essentially ineffective to mediate the activation of BaP by P450 1A1 reconstituted with POR 
(Figures 5B and 6), which again indicates that NADH functions as a coenzyme of POR at 
very slow rate that is negligible relative to NADPH.  
Human P450 1A1 reconstituted with CBR and cytochrome b5 also generated adduct 2. 
The presence of cytochrome b5 as a substrate of CBR and NADH as its cofactor was essential 
for this adduct formation; NADPH, the cofactor of POR, was ineffective (Figures 5B and 
6).No BaP-DNA adduct 2 was found when both NADPH and NADH were omitted from the 
incubation mixtures containing human recombinant P450 1A1 reconstituted with POR or 
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CBR (Figure 6). Levels of adduct 2 formed by human P450 1A1 in the presence of the 
NADH/cytochrome b5/CBR system were lower than those formed in the system of human 
P450 1A1 containing POR and NADPH (Figures 5 and 6). These results corresponded to 
lower levels of BaP-9-ol (a precursor of 9-hydroxy-BaP 4,5-epoxide generating this adduct)  
and other BaP metabolites formed in this system (see Figure S1). Significant correlations 
were found between levels of adduct 2 and BaP-9-ol (r = 0.943, P < 0.001, Spearman’s 
correlations) or BaP-3-ol (r = 0.943, P < 0.001), whereas no such correlations were found 
between levels of this adduct and BaP-1,6-dione, BaP-3,6-dione or a metabolite Mx (r < 0.5).  
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DISCUSSION 
The metabolism of BaP has been extensively studied over the past decades2 and various 
studies have examined the role of P450 enzymes, particularly P450 1A1 of several species, to 
metabolize this carcinogen.2,6,7,8,15,16,19,28,44 However, the mechanism of the reaction cycle of 
BaP oxidation catalyzed by P450 1A1, particularly the roles of POR and CBR as electron 
donors to P450 1A1, has not yet been fully resolved.7,8,15,19 Enigmatic results have been found 
in two mouse models where deletion of POR in hepatocytes did not lead to an expected 
decrease in BaP-DNA adduct formation in liver in vivo, but instead to higher BaP-DNA 
binding.7,8,19 We also showed that in livers of HRN mice P450 1A1, cytochrome b5 and mEH 
can effectively activate BaP to DNA binding species, even in the presence of very low 
amounts of POR.19 Because this feature has biological significance, studying the role of the 
enzymes reducing P450 1A1 is important to better understand the mechanism(s) involved in 
BaP metabolism. Recently we demonstrated that the NADH/cytochrome b5/CBR system is 
able to function as the sole donor of electrons for both reduction steps of rat P450 1A1 during 
BaP oxidation in vitro.15 This finding indicates that CBR as an NADH-dependent reductase 
might substitute POR in the P450 1A1-mediated BaP metabolism and might help to explain 
our enigmatic results in the POR-knockout mouse models.7,8,19 However, the question whether 
this novel function of the NADH/cytochrome b5/CBR system as electron donor to rat P450 
1A1 in BaP metabolism represents a general feature for the P450 1A1 reaction cycle in other 
species including humans remained to be answered. Therefore, the primary aim of this study 
was to determine whether the NADH/cytochrome b5/CBR system can be the exclusive donor 
of both electrons to the P450 1A1 human orthologue during BaP metabolism in vitro. To this 
end two enzymatic systems containing this human P450 were utilized: (1) microsomes of 
baculovirus-infected insect cells (Supersomes) containing human recombinant P450 1A1 
expressed with POR, CBR, mEH and cytochrome b5 and (2) pure human P450 1A1 
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heterologously expressed in E. coli reconstituted either with pure POR or CBR with 
cytochrome b5 in liposomes.  
Using the first system, human P450 1A1-Supersomes™, we proved that NADH acts as 
electron donor for both reductions of the P450 1A1 human orthologue in BaP oxidation 
independent of NADPH and POR if CBR and cytochrome b5 is present. This conclusion is 
supported by the fact that NADH functions as a poor coenzyme of POR when cytochrome c is 
used as its substrate.15 Our results therefore confirm the novel feature on the mechanism of 
the catalytic cycle of human P450 1A1 during BaP oxidation previously described for rat 
P450 1A1. We demonstrated that the reaction cycle of BaP oxidation catalyzed by human 
P450 1A1 can proceed by ways that differ from the generally accepted mechanism, where the 
first reduction of P450 is considered to be catalyzed by POR without cytochrome b5.20,48-52 
Considering the redox potentials of cytochrome b5 (+20 mV)53,54 and ferric substrate-bound 
P450 (‒237 mV)27,53 it is thermodynamically impossible for cytochrome b5 to provide the first 
electron in the P450 catalytic cycle55. Given that the redox potential of oxyferrous P450 is 
also approximately +20 mV, it is feasible that cytochrome b5 can supply the second electron 
into the catalytic cycle.27,53,55 However, based on the redox potential of CBR determined 
under the anaerobic conditions (‒265 mV)56 it could provide the first electron in the P450 
catalytic cycle.27,57 Moreover, considering the effect of Le Chatelier’s principle given, the 
reduced P450 will rapidly bind dioxygen under aerobic conditions of the experiments. Indeed, 
in the present study we demonstrate that the first reduction of P450 1A1 which previously had 
been considered to be mediated exclusively by the NADPH/POR system can be substituted by 
the NADH/cytochrome b5/CBR system. This reaction was found not only in Supersomes 
containing human recombinant P450 1A1, but, even more importantly, in the system of pure 
human P450 1A1 reconstituted with CBR and cytochrome b5. Such NADH/cytochrome 
b5/CBR-mediated activity of the human P450 1A1 systems was proven by the formation of up 
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to seven BaP metabolites [BaP-9,10-dihydrodiol (M1), BaP-7,8-dihydrodiol (M3), BaP-1,6-
dione (M4), BaP-3,6-dione (M5), BaP-9-ol (M6), BaP-3-ol (M7) and a metabolite of 
unknown structure (Mx)]. In addition, these systems generated two BaP-DNA adducts, the 
dG-N2-BPDE adduct (adduct 1) and/or a guanine adduct derived from the reaction with 9-
hydroxy-BaP-4,5-epoxide (adduct 2). The BaP metabolite profiles formed by P450 1A1 with 
the NADH/cytochrome b5/CBR system were the same as in the system where NADPH and 
POR were used as electron donors. BaP-4,5-dihydrodiol (M2), which was previously found to 
be formed by rat P450 1A115,19 was not generated by the human P450 1A1 orthologue (Figure 
2). This finding is in line with previous findings showing that this BaP metabolite was not 
formed in human bronchoalveolar H358 cells expressing P450 1A1 after BaP exposure.13 
Interestingly, essentially no differences in the levels of dG-N2-BPDE adducts were seen 
when using either NADPH or NADH as cofactors in the P450 1A1-Supersomes system (see 
Figure 4). However, it should be noted that the oxidation reaction of BaP to its metabolites 
was catalyzed less efficiently by NADH than by NADPH in this system (see Figure 2). One 
reason might be the effects of the different experimental conditions used for the incubations 
utilized for BaP metabolite analysis and BaP-DNA adduct formation (i.e. incubation times, 
concentrations of BaP, the presence or absence of DNA, see the Experimental Procedures 
section). 
In summary, this study demonstrates for the first time that NADH, CBR and cytochrome 
b5 can act as sole electron donors for both the first and second reduction of human P450 1A1 
during the oxidative metabolism of BaP and formation of BaP-DNA adducts in vitro. These 
findings confirm our results of a recent study where rat P450 1A1 was utilized to study BaP 
metabolism.15 However, although the role of the NADH/cytochrome b5/CBR system in both 
reductions of rat15 and human P450 1A1present work is proven in our in vitro studies, further 
investigations are needed in the future. In this context, the mechanism of both the first and 
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second reduction of P450 1A1 remains to be examined in detail. In addition, as shown by 
Guengerich and coworkers for the P450 3A4-mediated 6-hydroxylation of testosterone57, the 
question whether NADH/cytochrome b5/CBR system might also reduce other P450 enzymes 
needs to be addressed. This might be the case in rat hepatic microsomes where various P450s 
were induced by their specific inducers; in these microsomes, BaP was oxidized not only in 
the presence of NADPH, but also in the presence of NADH.15 Another crucial question that 
remains to be addressed relates to the impact of the NADH/cytochrome b5/CBR system on 
BaP metabolism in vivo. Recent in vivo experiments using cytochrome b5-knockout mouse 
lines (i.e. HBN and HBRN) provide evidence that in the absence of POR, cytochrome b5/CBR 
are capable of supplying electrons for P450 catalytic function (i.e. in metabolism of the P450 
3A substrate midazolam).27 It is anticipated that these mouse lines will help to elucidate the 
different mechanisms of P450-catalyzed BaP biotransformation in vivo. 
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Legends to Figures 
Figure 1. Proposed pathways of biotransformation and DNA adduct formation of BaP 
catalyzed by P450 1A1 and mEH. Upper, the typical three-step activation process by P450 
1A1 followed by hydrolysis by mEH leads to BPDE which forms dG-N2-BPDE (adduct 
1).Lower, the two-step activation process by P450 1A1 leads to the formation of 9-hydroxy-
BaP-4,5-epoxide that can react with deoxyguanosine in DNA (adduct 2). Insert: 
Autoradiographic profile of BaP-DNA adducts formed by human P450 1A1 in Supersomes™ 
with mEH in the presence of NADH and cytochrome b5 as evaluated by TLC 32P-postlabeling 
as described previously.19 
Figure 2. HPLC analysis of BaP metabolites formed by human recombinant P450 1A1 
expressed in Supersomes in the presence of NADPH (A). Structures of BaP metabolites 
formed by human P450 1A1 (B). Amounts of BaP metabolites formed by human recombinant 
P450 1A1 expressed in Supersomes™ in the presence of either NADPH or NADH and the 
effect of cytochrome b5 (cyt b5) on this metabolism (C). Note that besides human P450 1A1 
and POR over-expressed in Supersomes™, this enzymatic system also contained mEH and 
CBR. Values represent mean ± SD from three parallel measurements. ***P < 0.001 
(Student’s t-test), significantly different from incubations using NADPH as cofactor; ∆∆∆P < 
0.001 (Student’s t-test), significantly different from incubations without cytochrome b5. 
Figure 3. BaP metabolism catalyzed by human P450 1A1 reconstituted with POR or CBR 
with or without cytochrome b5 (cyt b5). Columns show the sum of individual BaP metabolites 
formed by P450 1A1 (BaP-3-ol, BaP-9-ol, BaP-1,6-dione, BaP-3,6-dione and the unknown 
metabolite Mx)  Incubations were carried out in the presence of NADPH or NADH. ∆∆∆P < 
0.001 (Student’s t-test), significantly different from incubations without cytochrome b5; ***P 
< 0.001 (Student’s t-test), significantly different from incubations with NADPH as cofactor. 
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Figure 4. DNA adduct formation (RAL, relative adduct labelling) by BaP activated with 
human recombinant P450 1A1 in Supersomes™ in the presence of either NADPH or NADH 
and the effect of cytochrome b5 (cyt b5) on this reaction. Note that besides P450 1A1 and POR 
over-expressed in Supersomes™, this enzymatic system also contained mEH and CBR. 
Values represent mean total RAL ± SD (n = 3; analyses of three independent in vitro 
incubations). ***P < 0.001 (Student’s t-test), levels of BaP-adduct 1 significantly different 
from incubations with NADH but without cytochrome b5. 
Figure 5. Autoradiographic profile of BaP-derived DNA adducts generated in DNA by BaP 
activated with human P450 1A1 in Supersomes™ with mEH in the presence of NADH and 
cytochrome b5 (A); with pure human P450 1A1 reconstituted with POR in liposomes in the 
presence of NADPH (B); P450 1A1 with POR in the presence of NADH; P450 1A1 with 
POR and cytochrome b5 in the presence of NADPH; P450 1A1 with POR and cytochrome b5 
in the presence of NADH; P450 1A1 with CBR and cytochrome b5 in the presence of 
NADPH; P450 1A1 with CBR and cytochrome b5 in the presence of NADH; P450 1A1 with 
cytochrome b5 in the presence of NADPH; and P450 1A1 with cytochrome b5 in the presence 
of NADH.  
Figure 6. The effect of NADPH and/or NADH on BaP-DNA adduct formation (RAL, relative 
adduct labelling) catalyzed by human recombinant P450 1A1 reconstituted with POR or CBR 
with or without cytochrome b5 in liposomes. Values are averages ± SD of three independent 
experiments. ***P < 0.001 (Student’s t-test), levels of BaP-adduct 2 significantly different 
from incubations with human P450 1A1, POR and NADPH. 
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